Status:
ACTIVE_NOT_RECRUITING
Progression of Early Subclinical Atherosclerosis
Lead Sponsor:
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Collaborating Sponsors:
Grupo Santander
Conditions:
Atherosclerosis
Eligibility:
All Genders
40-54 years
Brief Summary
The overall objective of this study is to characterize the prevalence and progression rate of subclinical atherosclerotic lesions and to study their association to the imaging characteristics of ather...
Detailed Description
Atherosclerosis is the most common cardiovascular disease and accounts for the greatest number of deaths. Atherosclerotic disease starts at an early age and follows a subclinical course for decades, b...
Eligibility Criteria
Inclusion
- Employees of the Banco de Santander Group
- Age between 40-54 years.
Exclusion
- Myocardial Infarction
- Angina pectoris
- Stroke, either transient or with sequelae
- Peripheral vascular disease
- Prior angioplasty or heart surgery
- Atrial fibrillation
- Other heart diseases
- Subjects with the following conditions will also be excluded:
- Pregnancy
- Active treatment for any cancer
- Morbid obesity (BMI ≥40)
- Renal failure with creatinine clearance \<60 mL/min, as estimated by the Cockcroft and Gault formula
- Any disease that decreases life expectation to ≤6 years
- Pacemaker, implantable automatic defibrillator, or any implanted device that contraindicates MRI
- A chest CT in the previous year
Key Trial Info
Start Date :
June 14 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2030
Estimated Enrollment :
4184 Patients enrolled
Trial Details
Trial ID
NCT01410318
Start Date
June 14 2010
End Date
June 1 2030
Last Update
April 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ciudad Financiera del Grupo Santander
Boadilla del Monte, Madrid, Spain, 28660